Switch theme
Sign up to access all valuation multiples
Tchaikapharma Highquality Medicines AD is engaged in the business of manufacturing and selling pharmaceuticals in Bulgaria. It manufactures medicines for cancer, heart diseases, respiratory problems, and neurological diseases, among others.
2000
191
LTM Revenue n/a
LTM EBITDA n/a
$888M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TchaikaPharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, TchaikaPharma achieved revenue of $29.4M and an EBITDA of $4.8M.
TchaikaPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TchaikaPharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $26.8M | $29.4M | XXX | XXX | XXX |
| Gross Profit | $7.2M | $8.3M | XXX | XXX | XXX |
| Gross Margin | 27% | 28% | XXX | XXX | XXX |
| EBITDA | $4.0M | $4.8M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 16% | XXX | XXX | XXX |
| Net Profit | $1.5M | $1.9M | XXX | XXX | XXX |
| Net Margin | 6% | 6% | XXX | XXX | XXX |
| Net Debt | $5.3M | $5.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TchaikaPharma's stock price is BGN 17 (or $10).
TchaikaPharma has current market cap of BGN 1.6B (or $882M), and EV of BGN 1.6B (or $888M).
See TchaikaPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $888M | $882M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TchaikaPharma has market cap of $882M and EV of $888M.
TchaikaPharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate TchaikaPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TchaikaPharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $888M | XXX | XXX | XXX |
| EV/Revenue | 30.2x | XXX | XXX | XXX |
| EV/EBITDA | 184.5x | XXX | XXX | XXX |
| P/E | 317.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 478.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTchaikaPharma's NTM/LTM revenue growth is n/a
TchaikaPharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $34K for the same period.
Over next 12 months, TchaikaPharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TchaikaPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TchaikaPharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $34K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 22% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TchaikaPharma acquired XXX companies to date.
Last acquisition by TchaikaPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . TchaikaPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TchaikaPharma founded? | TchaikaPharma was founded in 2000. |
| Where is TchaikaPharma headquartered? | TchaikaPharma is headquartered in Bulgaria. |
| How many employees does TchaikaPharma have? | As of today, TchaikaPharma has 191 employees. |
| Is TchaikaPharma publicy listed? | Yes, TchaikaPharma is a public company listed on BUL. |
| What is the stock symbol of TchaikaPharma? | TchaikaPharma trades under THQM ticker. |
| When did TchaikaPharma go public? | TchaikaPharma went public in 2012. |
| Who are competitors of TchaikaPharma? | Similar companies to TchaikaPharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of TchaikaPharma? | TchaikaPharma's current market cap is $882M |
| What is the current revenue growth of TchaikaPharma? | TchaikaPharma revenue growth between 2023 and 2024 was 10%. |
| Is TchaikaPharma profitable? | Yes, TchaikaPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
